Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • DBV Technologies...

    DBV Technologies peanut allergy drug fails key study

    Written by Ruby Khatun Khatun Published On 2017-10-23T09:15:06+05:30  |  Updated On 18 Aug 2021 3:35 PM IST

    DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.


    Nasdaq-listed shares of the French drug developer plunged 60.5 percent to $19 in extended trading.


    The trial, which tested a 250 microgram stick-on patch called Viaskin Peanut, in 356 children between the ages of 4-11, missed the main goal of achieving a certain tolerance to peanut protein.



    Shares of rival Aimmune Therapeutics Inc, which is developing an oral peanut allergy pill, soared about 40 percent to $35.65 after market.

    Aimmune is expected to announce results of its late-stage trial early next year.


    Preliminary results of DBV's trial show 12 months of the treatment resulted in 35.3 percent of patients achieving a certain tolerance, versus a higher-than-expected 13.6 percent response from a placebo group.


    However, DBV said the results showed a statistically significant response with a favorable tolerability profile.


    Plans to submit a marketing application for the patch to the U.S. Food and Drug Administration (FDA) next year remain unchanged, the company said.


    DBV is also testing a similar patch to treat cow milk-related allergies in a mid-stage trial, the results of which are expected early next year.


    Leerink analyst Dae Gon Ha estimated DBV's peak sales, including the peanut and milk allergy patches, of about 1.8 billion euros ($2.12 billion) in 2027.


    There are currently no U.S. regulator-approved treatments for peanut allergies, the leading cause of death from food-induced allergic reactions in the United States.


    The market is desperate for recourse, experts say, as peanut allergies have more than doubled in children from 1997 to 2008, and affect about two percent, American children.


    Those afflicted risk potentially fatal anaphylaxis, a severe allergic reaction, even if exposed to trace amounts of peanut protein.


    Viaskin Peanut, which must be replaced daily, delivers peanut protein to patients' immune systems via the skin, desensitizing them to small doses of the allergen over time.


    Unlike an oral drug, the patch avoids contact with the bloodstream, lessening the risk of adverse reactions, DBV told Reuters.


    Earlier this month, Aimmune said it planned to test its pill in a mid-stage trial with Regeneron Pharmaceuticals Inc's and Sanofi's drug dupilumab.




    (Reporting by Tamara Mathias in Bengaluru; Editing by Shounak Dasgupta)



    Aimmune TherapeuticsDBV Technologiesdupilumabfailskey studypeanut allergy drugpharma newsRegeneronSanofiSharesU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok